Auto Amazon Links: No products found. Blocked by captcha.
A groundbreaking medication is making a significant difference for children affected by a severe form of epilepsy, according to doctors and families alike. This condition, Dravet syndrome, is a rare genetic disorder occurring in approximately one in every 15,000 births. It causes dangerous seizures that can occur dozens of times daily, posing serious risks of injury and even death if left untreated.
The innovative drug, zorevunersen, is delivered directly into the spinal fluid via infusion. It addresses the root cause of the syndrome, which, in most cases, is a mutation in the SCN1A gene responsible for producing sodium channels necessary for proper brain cell communication. By promoting increased production of these channels, zorevunersen helps reduce seizure frequency and severity in affected children.
One of the first young patients to benefit from this treatment in the UK is eight-year-old Freddie Truelove from Huddersfield. Prior to receiving the drug, Freddie experienced hundreds of seizures daily, but now he has only a few per week. His mother, Lauren, described the medication as transformative, saying, “We now have a life we didn’t ever think was possible and, most importantly, it’s a life that Freddie can enjoy.” She shared how Freddie has been able to participate in activities they never imagined possible before, including hiking, walking by lakes, and even skiing.
Initial findings, recently published in the New England Journal of Medicine, indicate that zorevunersen can be safely administered to children as young as two years old. The treatment continues to be trialed in both the UK and the US, with many participants, including Freddie, continuing on the therapy as part of ongoing research. While further studies are required to establish long-term effectiveness before widespread clinical use, experts and advocacy groups express optimism. Galia Wilson, chair of trustees for Dravet Syndrome UK, emphasized the hope this treatment brings, highlighting the tremendous impact of the condition and anticipating the forthcoming Phase Three trials to confirm these promising early results
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.